ArticleJournal of robotic surgery2026
Incidence, predictors, and prognostic impact of pathological T3a upstaging after robot-assisted partial nephrectomy for clinical T1-T2 renal cell carcinoma.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Upstaging to pT3a has been associated with adverse oncologic outcomes; however, previous studies included mixed partial and radical nephrectomy cohorts, potentially introducing selection bias. Data focusing on robot-assisted partial nephrectomy (RAPN) remain limited. This study aimed to evaluate the incidence, preoperative predictors, and prognostic impact of pT3a upstaging in a large RAPN cohort. We retrospectively analyzed patients with clinical T1–T2 renal cell carcinoma who underwent RAPN between January 2010 and May 2025. Demographic, radiologic, and laboratory variables, including inflammatory and nutritional indices, were collected and analyzed. Logistic regression was used to identify predictors of pT3a upstaging. Local recurrence–free survival (LRFS) and metastasis-free survival (MFS) were assessed using Kaplan–Meier and Cox regression analyses. Receiver operating characteristic (ROC) analysis was performed to determine the optimal RENAL score cutoff. Among 2,016 patients, pT3a upstaging occurred in 38 (1.9%) during a median follow-up of 37 months. Older age (OR, 1.04; 95% CI, 1.01–1.08; p = 0.007) and higher RENAL score (OR, 1.35; 95% CI, 1.16–1.59; p < 0.001) were independent predictors. A RENAL score cutoff of ≥ 7 was identified (area under the ROC curve, 0.65; 95% CI, 0.56–0.74), with a high negative predictive value for occult pT3a disease (99.3%). Overall, pT3a upstaging was not independently associated with LRFS or MFS. In subgroup analysis according to invasion pattern, venous invasion was associated with an increased risk of metastasis (HR, 6.14; 95% CI, 1.12–33.75; p = 0.037), whereas fat-only invasion was not. Pathological upstaging to pT3a after RAPN is rare and primarily associated with tumor complexity and patient age. Although overall upstaging does not adversely affect oncologic outcomes, venous invasion represents a high-risk subgroup for metastatic progression.
Indexed as
Identifiers
41910899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.